Listar MD - Artículos por autor "Pérez-Ruiz, Elisabeth"
Mostrando ítems 1-3 de 3
-
Association of Circular RNA and Long Non-Coding RNA Dysregulation with the Clinical Response to Immune Checkpoint Blockade in Cutaneous Metastatic Melanoma.
Oliver, Javier; Onieva Zafra, Juan Luis; Garrido-Barros, María; Berciano-Guerrero, Miguel Ángel; Sánchez-Muñoz, Alfonso
; Lozano, María José; Farngren, Angela; Álvarez-Pérez, Martina; Martínez-Gálvez, Beatriz; Pérez-Ruiz, Elisabeth; Alba-Conejo, Emilio; Cobo Dols, Manuel Ángel; Rueda-Domínguez, Antonio; Barragán, Isabel[et al.] (MDPI, 2022)
Cutaneous melanoma (CM) is the most lethal form of skin cancer if it becomes metastatic, where treatment options and survival chances decrease dramatically. Immunotherapy treatments based on the immunologic checkpoint ... -
Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
Sánchez-Muñoz, Alfonso; Mendiola, César; Pérez-Ruiz, Elisabeth; Rodríguez-Sánchez, César A.; Jurado, José Miguel; Alonso-Carrión, Lorenzo Javier; Ghanem, Ismael; Velasco, Guillermo de; Quero-Blanco, Cristina; Alba-Conejo, Emilio[et al.] (KARGER, 2010-11)
Aim: To retrospectively assess the efficacy and safety of bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer. Patients and Methods: Patients with recurrent ... -
High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva Zafra, Juan Luis; Xiao, Qingyang; Berciano-Guerrero, Miguel Ángel; Laborda-Illanes, Aurora; de Andrea, Carlos; Chaves, Patricia; Piñeiro Pereda, María del Pilar; Garrido-Aranda, Alicia; Gallego-Domínguez, Elena María; Sojo, Belén; Gálvez Carvajal, Laura; Chica Parrado, María del Rosario; Prieto Cuadra, Juan Daniel; Pérez-Ruiz, Elisabeth; Farngren, Angela; Lozano, María José; Álvarez-Pérez, Martína; Jiménez, Pedro; Sánchez-Muñoz, Alfonso; Oliver, Javier; Cobo Dols, Manuel Ángel; Alba-Conejo, Emilio; Barragán, Isabel[et al.] (MDPI, 2022)
Resistance to Immune Checkpoint Blockade (ICB) constitutes the current limiting factor for the optimal implementation of this novel therapy, which otherwise demonstrates durable responses with acceptable toxicity scores. ...